Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  CAS  Google Scholar 

Oronsky B, Abrouk N, Caroen S, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13(9):2945–53. https://doi.org/10.7150/jca.75622.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0.

Article  PubMed  PubMed Central  Google Scholar 

Sathiyapalan A, Febbraro M, Pond GR, et al. Chemo-immunotherapy in first line extensive stage small cell lung Cancer (ES-SCLC): a systematic review and meta-analysis. Curr Oncol. 2022;29(12):9046–65. https://doi.org/10.3390/curroncol29120709.

Article  PubMed  PubMed Central  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39. https://doi.org/10.1016/s0140-6736(19)32222-6.

Article  PubMed  CAS  Google Scholar 

Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical oncology endorsement of the American College of chest physicians guideline. J Clin Oncol. 2015;33(34):4106–11. https://doi.org/10.1200/jco.2015.63.7918.

Article  PubMed  CAS  Google Scholar 

Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8. https://doi.org/10.1200/jco.2011.40.4905.

Article  PubMed  CAS  Google Scholar 

Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47. https://doi.org/10.1016/s1470-2045(22)00224-8.

Article  PubMed  CAS  Google Scholar 

Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064.

Article  PubMed  CAS  Google Scholar 

Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408. https://doi.org/10.1016/j.esmoop.2022.100408.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–30. https://doi.org/10.1200/jco.20.01055.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223–32. https://doi.org/10.1001/jama.2022.16464.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079–90. https://doi.org/10.1007/s00262-018-2160-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024. https://doi.org/10.1016/j.jtho.2024.03.008.

Article  PubMed  Google Scholar 

Gong J, Su D, Shang J, et al. Cost-effectiveness of tislelizumab versus docetaxel for previously treated advanced non-small-cell lung cancer in China. Front Pharmacol. 2022;13:830380. https://doi.org/10.3389/fphar.2022.830380.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liang X, Chen X, Li H, et al. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer. Front Public Health. 2023;11:1009920. https://doi.org/10.3389/fpubh.2023.1009920.

Article  PubMed  PubMed Central  Google Scholar 

Luo X, Zhou Z, Zeng X, et al. The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer. Front Pharmacol. 2022;13:935581. https://doi.org/10.3389/fphar.2022.935581.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang X, Fan X, Zhang J, et al. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China. Front Public Health. 2024;12:1425734. https://doi.org/10.3389/fpubh.2024.1425734.

Article  PubMed  PubMed Central  Google Scholar 

Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. https://doi.org/10.1016/j.jval.2021.11.1351.

Article  PubMed  Google Scholar 

Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441–64. https://doi.org/10.6004/jnccn.2021.0058.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836–45. https://doi.org/10.1016/j.jval.2011.04.004.

Article  PubMed  Google Scholar 

Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996–2016. JAMA. 2020;323(9):863–84. https://doi.org/10.1001/jama.2020.0734.

Article  PubMed  PubMed Central  Google Scholar 

Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2):e210037. https://doi.org/10.1001/jamanetworkopen.2021.0037.

Article  PubMed  PubMed Central  Google Scholar 

Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1–5. https://doi.org/10.1016/j.vhri.2020.07.580.

Article  PubMed  CAS  Google Scholar 

Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–51. https://doi.org/10.1002/(sici)1099-1050(200004)9:3%3c235::aid-hec502%3e3.0.co;2-o.

Article  PubMed  CAS  Google Scholar 

Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7. https://doi.org/10.1056/NEJMp1405158.

Article  PubMed  CAS  Google Scholar 

Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.